# A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

> **NCT04557462** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 540 (estimated)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT04557462
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-20
- **Primary completion:** 2030-12-04
- **Final completion:** 2030-12-04
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557462, "A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04557462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*